<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812473</url>
  </required_header>
  <id_info>
    <org_study_id>ML8949</org_study_id>
    <secondary_id>2013-000559-42</secondary_id>
    <nct_id>NCT01812473</nct_id>
  </id_info>
  <brief_title>Plasma Protein Binding Characteristics of Voriconazole</brief_title>
  <official_title>Plasma Protein Binding Characteristics of Voriconazole in Specific Subsets of Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the protein binding characteristics of the
      antifungal drug voriconazole in different patient populations, both to albumin and
      alpha-1-acid-glycoprotein.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Differences in overall protein binding between different patient groups</measure>
    <time_frame>At steady state plasma concentration of voriconazole (after day 4 of therapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>At steady state plasma concentrations of voriconazole, a plasma sample is taken to determine the overall protein binding of voriconazole. Equilibrium dialysis is used, followed by liquid chromatography-mass spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein binding characteristics of voriconazole to albumin and alpha-1-acid-glycoprotein</measure>
    <time_frame>At steady state plasma concentration of voriconazole (after day 4 of therapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>At steady state plasma concentrations of voriconazole, at the same time of plasma sampling for overall protein binding determination, albumin level is determined. A serum sample is also taken to determine the alpha-1-acid-glycoprotein. In this way, variations in overall protein binding can be correlated with variations in both plasma proteins.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Focus of the Study:Protein Binding Characteristics of Voriconazole.</condition>
  <arm_group>
    <arm_group_label>Patients admitted to the Intensive Care Unit</arm_group_label>
    <description>All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients admitted to the hematology ward</arm_group_label>
    <description>All patients admitted to the Hematology ward, treated with voriconazole are eligible for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients admitted to the pediatric ward</arm_group_label>
    <description>All patients admitted to the Pediatric ward, treated with voriconazole are eligible for the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.</description>
    <arm_group_label>Patients admitted to the Intensive Care Unit</arm_group_label>
    <arm_group_label>Patients admitted to the hematology ward</arm_group_label>
    <arm_group_label>Patients admitted to the pediatric ward</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum samples are obtained to determine the albumin and alpha-1-acid-glycoprotein
      level.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the intensive care unit, hematology ward, pediatric ward, treated
        with voriconazole.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  treated with voriconazole

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Vanstraelen, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Vanstraelen, PharmD</last_name>
    <phone>(+32) (0) 16 342339</phone>
    <email>kim.vanstraelen@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kim Vanstraelen, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Spriet, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joost Wauters, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Maertens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrien Lagrou, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>protein binding</keyword>
  <keyword>voriconazole</keyword>
  <keyword>pediatrics</keyword>
  <keyword>hematology</keyword>
  <keyword>intensive care</keyword>
  <keyword>albumin</keyword>
  <keyword>alpha-1-acid-glycoprotein</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
